UBS upgraded CVS Health stock to a Buy rating, noting that CVS operates through its Aetna subsidiary.
4 reports, 1 independent
Updated Jul 25
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS upgraded CVS Health stock to a Buy rating, noting that CVS operates through its Aetna subsidiary.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Aetna
American managed health care company
-
CVS Health
company
-
UBS
Swiss multinational investment bank and financial services company
Related events
- Intensifying competition over market share and drug efficacy is occurring among major pharmaceutical companies, alongside the established corporate structure of CVS and Aetna.
- Teladoc, CVS Health, and Aetna formed a partnership focused on digital health services, with headquarters located in Woonsocket, RI.
- HSBC restated its 'hold' rating on CVS Health, while Manufacturers Life Insurance Company increased its stake in the company's shares.
- CVS Health is expanding its drug offerings to include Eli Lilly's Zepbound and Novo Nordisk's Wegovy, while also considering an investment in Roche.
- Oscar Health and CVS Health are identified as health insurance providers in the market segment.
Coverage
Newest first; wire copies grouped- Insider MonkeyJefferies Reiterates a Buy Rating on CVS Health (CVS) With a PT of $80 CVS Health Corporation (NYSE:CVS) is one of the top most undervalued low volatility stocks to buy now. In a report released on A